Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.

Gabapentin improves symptoms of functional dyspepsia

14 Apr 2019

Treatment with gabapentin significantly improves symptoms of functional dyspepsia in a retrospective, open-label cohort of patients, reports an open-label study.

Sixty-two of the 110 patients with functional dyspepsia completed pre- and postgabapentin surveys. A 0.44-decrease (p<0.0001) was observed in the patients’ mean Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM), with significant changes in all subscales, including upper abdominal pain, lower abdominal pain and postprandial fullness, except for bloating.

An independent association was seen between worsening pretreatment symptom severity and improvement in multivariable analysis. Gabapentin treatment was discontinued in seven (11.3 percent) patients, with five (71.4 percent) stopping due to side effects.

There were significant improvements in overall, postprandial fullness and upper abdominal pain subscores in ≥50 percent of the cohort using the minimum significant PAGI-SYM score change threshold.

“Further studies are needed to place gabapentin in the functional dyspepsia treatment algorithm,” the authors said, adding that the findings were limited by the open-label design of the study.

Prior to evaluation, a baseline PAGI-SYM was completed by consecutive patients presenting to a tertiary motility clinic for the evaluation of functional dyspepsia without concurrent gastric emptying delay. Providers also initiated these patients on gabapentin for functional dyspepsia. Change in total PAGI-SYM score between initial and subsequent visits was the primary endpoint.

“Gabapentin has an established role in the treatment of neuropathic pain, with evidence supporting a benefit in visceral hypersensitivity. There is currently no data on the use of gabapentin for the treatment of functional dyspepsia,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.